Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa—Ethiopia, Kenya, Rwanda, and Tanzania

Autor: Barry, Abbie, Olsson, Sten, Khaemba, Christabel, Kabatende, Joseph, Dires, Tigist, Fimbo, Adam, Minzi, Omary, Bienvenu, Emile, Makonnen, Eyasu, Kamuhabwa, Appolinary, Oluka, Margaret, Guantai, Anastasia, van Puijenbroek, Eugène, Bergman, Ulf, Nkayamba, Alex, Mugisha, Michael, Gurumurthy, Parthasarathi, Aklillu, Eleni
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: International Journal of Environmental Research and Public Health, Vol 18, Iss 1941, p 1941 (2021)
International Journal of Environmental Research and Public Health
Volume 18
Issue 4
ISSN: 1661-7827
1660-4601
Popis: Monitoring the safety of medicines used in public health programs (PHPs), including the neglected tropical diseases (NTD) program, is a WHO recommendation, and requires a well-established and robust pharmacovigilance system. The objective of this study was to assess the pharmacovigilance systems within the NTD programs in Ethiopia, Kenya, Rwanda, and Tanzania. The East African Community Harmonized Pharmacovigilance Indicators tool for PHPs was used to interview the staff of the national NTD programs. Data on four components, (i) systems, structures, and stakeholder coordination
(ii) data management and signal generation
(iii) risk assessment and evaluation
and (iv) risk management and communication, were collected and analyzed. The NTD programs in the four countries had a strategic master plan, with pharmacovigilance components and mechanisms to disseminate pharmacovigilance information. However, zero individual case safety reports were received in the last 12 months (2017/2018). There was either limited or no collaboration between the NTD programs and their respective national pharmacovigilance centers. None of the NTD programs had a specific budget for pharmacovigilance. The NTD program in all four countries had some safety monitoring elements. However, key elements, such as the reporting of adverse events, collaboration with national pharmacovigilance centers, and budget for pharmacovigilance activity, were limited/missing.
Databáze: OpenAIRE
Externí odkaz: